Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Phase 2
Active, not recruiting
- Conditions
- Long COVIDPost Acute Sequelae of COVID-19Post-Acute COVID-19
- Interventions
- Other: Placebo
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Timothy Henrich
- Target Recruit Count
- 40
- Registration Number
- NCT06161688
- Locations
- 🇺🇸
UCSF/Zuckerberg San Francisco General Hospital, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath